Longitudinal stability of JCV antibody index in Natalizumab treated people with multiple sclerosis

Objective: The aim of this study was to evaluate the evolution of JCV index over time in Natalizumab treated people with multiple sclerosis. Materials and Methods: We retrospectively reviewed antibody index values from pwMS who were treated with Natalizumab for greater than six months and had at least two antibody results available between 2011 and 2019. Survival analysis was performed on those who were JCV index value negative at baseline to evaluate time to seroconversion. In pwMS who had index values available at 48 and/or 96 months post Natalizumab initiation, t -tests were performed to evaluate change in index over time.Results: 1144 JCV antibody index results were available for 132 pwMS. Median time to seroconversion based on survival analysis was 103 months. Annualised seroconversion rate was 5.8%. Initial antibody index and rate of seroconversion did not differ with regards to age or gender. Antibody index increased significantly over time on treatment for the cohort as a whole, initial antibody index (0.27) to final antibody testing (0.86), t(131)=6.45, p<.0005. There was a significant increase in those with initial positive index value, between first (0.95) and final index (2.14), t(33) = 4.85, p<.0005 over a median of 77 months.Conclusions: In those who were seronegative at baseline there is a long median duration of treatment with Natalizumab prior to seroconversion. In individuals with positive JCV antibody index at treatment initiation, antibody index increases over time.

Automated summary

This study evaluated the evolution of the JCV index over time in individuals with multiple sclerosis treated with natalizumab. The findings showed that individuals who were seronegative at baseline had a long duration of treatment before seroconversion, while those with positive JCV antibody index at treatment initiation experienced an increase in antibody index over time.